Arsenal Biosciences Raises $325M in Series C Financing Round

September 5, 2024

Arsenal Biosciences raised $325M in Series C to advance CAR T-cell therapies for solid tumors, with AB-1015 for ovarian cancer and AB-2100 for kidney cancer in early clinical development.

Related Clinical Trials

AB-2100, an Integrated Circuit T (ICT) Cell Therapy in Patients with Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Reference News

precisionmedicineonline.com

Arsenal Biosciences Raises $325M in Series C Financing Round

Arsenal Biosciences raised $325M in Series C to advance CAR T-cell therapies for solid tumors, with AB-1015 for ovarian cancer and AB-2100 for kidney cancer in early clinical development.